Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01940991 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 82
- Enrollment target
NCT01940991 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 82 participants.
The verdict
NCT01940991, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 82 participants
- Enrollment target
Study Summary
This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
Interventions
- DRUG Placebo
- DRUG Botulinum Toxin Type A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01940991
The ClinicalTrials.gov registry entry for NCT01940991 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01940991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01940991 about?
NCT01940991 is a clinical study titled "Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines". This study will confirm the efficacy and safety of a single topical administration of botulinum toxin type A compared to placebo control for the treatment of moderate to severe crow's feet lines
What is the current status of trial NCT01940991?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 82 participants. The study started on 2013-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01940991?
The interventions under investigation include: Placebo (DRUG), Botulinum Toxin Type A (DRUG).
Who is sponsoring clinical trial NCT01940991?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.